

Metabolismo, Sistemas Modelo y Terapias para la ELA.

Tercer Encuentro Internacional de Investigación en ELA en España

Metabolism, Model Systems and Therapies for ALS.

Madrid, 2 de julio / July 2 2019

BIO

Kevin Talbot

Kevin Talbot qualified in medicine (MB BS) with Distinction from the University of London and trained in Neurology in London and Oxford. He joined the laboratory of Professor Kay Davies in 1995 to work on the childhood motor neuron disorder spinal muscular atrophy, which has remained a major focus of his research ever since. From 1998-2001 he was Clinical Lecturer in Neurology and from 2001-2006 held an MRC Clinician Scientist Fellowship. He leads a multidisciplinary team providing a clinical service for patients with motor neuron disease from all over the South of England. In 2010 he became Professor of Motor Neuron Biology.

The main aim of his research is to identify targets for therapy in motor neuron diseases such as amyotrophic lateral sclerosis and spinal muscular atrophy. In particular, he use laboratory models including motor neurons from induced pluripotent stem cells from patients to understand why motor neuron integrity fails in the presence of certain genetic mutations (eg; TDP-43 or C9orf72 in ALS). In his lab, they also use these models to identify drug targets. Their work takes place in the context of a larger team of researchers in Oxford interested in translational research in neurodegenerative diseases, and they have many national and international collaborations.